By combining the Gleason score (determined by a pathologist examining cancer cells under a microscope), the clinical stage (determined by a careful prostate exam and various scans) and the PSA level, we can stratify patients into "low, " "intermediate" and "high" risk categories.

WSJ: Are PSA Tests a Good Idea for Screening Men for Prostate Cancer?